To learn more about these conditions and how Praluent helps treat them, see the “What is Praluent used for?” section below. Praluent is given as an injection under your skin. Praluent contains the ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded indication for alirocumab injection for adult patients with homozygous ...
Paris and Tarrytown, NY - September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License ...
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs ...
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein ...
BARCELONA, SPAIN — Treatment with alirocumab (Sanofi/Regeneron Pharmaceuticals), an investigational proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in significant reductions ...
PARIS, FRANCE and TARRYTOWN, NY – Alirocumab (Sanofi/Regeneron Pharmaceuticals), a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), effectively lowered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results